Pershing Square Rolls Valeant Options Exposure From 2017 to 2019 ~ market folly

Monday, June 13, 2016

Pershing Square Rolls Valeant Options Exposure From 2017 to 2019

Bill Ackman's hedge fund firm Pershing Square Capital Management has filed an amended 13D with the SEC regarding its position in Valeant Pharmaceuticals (VRX).  Per the filing, Pershing now owns 9.0% of VRX with 30.71 million shares.

The filing also notes that Pershing has closed its January 2017 options positions and opened similar positions in options expiring January 2019.  Basically, they've rolled their exposure back 2 years.

Pershing bought call options and sold put options and you can view the entire list of transactions here.

Other investors have also been active in this stock, as we highlighted how Ruane Cunniff sold half of its VRX stake recently.

For more on Bill Ackman's firm, we detailed how Pershing Square sold some Zoetis as well.

Per Google Finance, Valeant is "a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products."

blog comments powered by Disqus